Association of Serum Interleukin-17 and Interleukin-23 Levels with Disease Activity, Function, Mobility, Enthesitis Index in Patients with Ankylosing Spondylitis

Abstract

Aim: More and more studies have demonstrated that the interleukin (IL)-23/IL-17 axis is highly associated with immune dysfunction and activated autoimmune inflammation. The purposes of this study were to determine the serum levels of IL-17 and IL-23 in ankylosing spondylitis (AS) patients compared with healthy controls and evaluate these cytokine levels based on disease-related characteristics. Material and Methods: Eighty-six consecutive AS patients and 70 sex and age-matched healthy controls were included in the study. The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), the Ankylosing Spondylitis Disease Activity Score (ASDAS)-erythrocyte sedimentation rate (ESR), ASDAS-C reactive protein, the Bath Ankylosing Spondylitis Functional Index (BASFI), the Spondyloarthritis Research Consortium of Canada (SPARCC) enthesitis index, the Bath Ankylosing Spondylitis Metrology Index (BASMI), the Ankylosing Spondylitis Quality of Life Questionnaire (ASQoL) and Achilles pain VAS scores were recorded. Serum IL-17 and IL-23 levels were examined by enzyme-linked immunosorbent assay. Results: The serum levels of IL-17, IL-23 and CRP as well as ESR values were significantly increased in AS patients compared with controls (1.94 vs. 0.28 pg/mL p ˂ 0.001; 82.9 vs. 44.3 pg/mL p ˂ 0.001; 0.48 vs. 0.30 mg/dL, p=0.001; 12±13.9 vs. 8±6.8 mm/h, p=0.003, respectively). In AS patients, serum IL-17 levels were significantly correlated with the ASDAS-ESR and ASDAS-CRP (r=0.244, p=0.024; r=0.258, p=0.017), but not with ESR, CRP, BASDAI, function, mobility, quality of life, enthesitis index or Achilles pain scores (all p>0.05). Serum IL-23 levels demonstrated a significant correlation with Achilles pain VAS, but not with other disease-related parameters (all p>0.05). Conclusions: AS patients had increased serum IL-17 and IL-23 levels compared with healthy controls, and serum IL-17 levels were associated with disease activity. Our study results support the hypothesis that the IL17/23 pathway plays an important role in the pathogenesis of AS.

Zusammenfassung

Ziel der Arbeit: Immer mehr Studien zeigen, dass die Interleukin(IL)-23/IL-17-Achse in hohem Maße mit einer Immundysfunktion und einer aktivierten Autoimmunentzündung assoziiert ist. Ziel dieser Studie war die Bestimmung der Serumspiegel von IL-17 und IL-23 bei Patienten mit ankylosierender Spondylitis (AS) im Vergleich zu gesunden Kontrollprobanden und die Bewertung dieser Zytokinspiegel anhand von krankheitsbezogenen Merkmalen. Material und Methoden: Sechsundachtzig konsekutive AS-Patienten und 70 gesunde Kontrollprobanden gleichen Geschlechts und Alters wurden in die Studie eingeschlossen. Dokumentiert wurden der Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), der Ankylosing Spondylitis Disease Activity Score (ASDAS)-Erythrozytensedimentationsrate (ESR), ASDAS-C-reaktives Protein (CRP), der Bath Ankylosing Spondylitis Functional Index (BASFI), der Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis-Index, der Bath Ankylosing Spondylitis Metrology Index (BASMI), der Ankylosing Spondylitis Quality of Life Questionnaire (ASQoL) sowie Achillessehnenschmerz-Scores (VAS). Die Serumspiegel von IL-17 und IL-23 wurden mithilfe eines enzymgebundenen Immunadsorptionstests untersucht. Ergebnisse: Die Serumspiegel von IL-17, IL-23 und CRP sowie die ESR-Werte waren bei AS-Patienten im Vergleich zu den Kontrollen signifikant erhöht (1,94 vs. 0,28 pg/ml, p ˂ 0,001; 82,9 vs. 44,3 pg/ml, p ˂ 0,001; 0,48 vs. 0,30 mg/dl, p=0,001; 12±13,9 vs. 8±6,8 mm/h, p=0,003). Bei AS-Patienten korrelierten die IL-17-Spiegel im Serum signifikant mit ASDAS-ESR und ASDAS-CRP (r=0,244, p=0,024; r=0,258, p=0,017), aber nicht mit ESR, CRP, BASDAI, Funktion, Mobilität, Lebensqualität, Enthesitis-Index oder Achillessehnenschmerz-Scores (alle p>0,05). Die Serum-IL-23-Spiegel zeigten eine signifikante Korrelation mit der VAS Achillessehnenschmerz, aber nicht mit anderen krankheitsbezogenen Parametern (alle p>0,05). Schlussfolgerung: AS-Patienten hatten im Vergleich zu den gesunden Kontrollpersonen erhöhte IL-17- und IL-23-Serumspiegel und die IL-17-Serumspiegel waren mit der Krankheitsaktivität assoziiert. Unsere Studienergebnisse unterstützen die Hypothese, dass der IL17/23-Signalweg eine wichtige Rolle bei der Pathogenese von AS einnimmt.

Key words

ankylosing spondylitis - interleukin-17 - interleukin-23

Schlüsselwörter

Interleukin-17 - Interleukin-23 - ankylosierende Spondylitis

Publikationsverlauf

Artikel online veröffentlicht:
23. November 2022

• References

• 1 Chisălău BA, Crînguș LI, Vreju FA. et al. New insights into IL-17/IL-23 signaling in ankylosing spondylitis (Review). Exp Ther Med 2020; 20: 3493-3497
• 2 Wang P, Zhang S, Hu B. et al. Efficacy and safety of interleukin-17A inhibitors in patients with ankylosing spondylitis: a systematic review and meta-analysis of randomized controlled trials. Clin Rheumatol 2021; 40: 3053-3065
• 3 Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet 2017; 1 390: 73-84
• 4 International Genetics of Ankylosing Spondylitis Consortium (IGAS). Cortes A, Hadler J, Pointon JP. et al. Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci Nat Genet. 2013 45. 730-738
• 5 Hreggvidsdottir HS, Noordenbos T, Baeten DL. Inflammatory pathways in spondyloarthritis. Mol Immunol 2014; 57: 28-37
• 6 Tsukazaki H, Kaito T. The Role of the IL-23/IL-17 Pathway in the Pathogenesis of Spondyloarthritis. Int J Mol Sci 2020; 21: 6401
• 7 Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 361-368
• 8 Garrett S, Jenkinson T, Kennedy LG. et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21: 2286-2291
• 9 Machado P, Landewé R, Lie E. et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 2011; 70: 47-53
• 10 Calin A, Garrett S, Whitelock H. et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994; 21: 2281-2285
• 11 Jenkinson TR, Mallorie PA, Whitelock HC. et al. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 1994; 21: 1694-1698
• 12 Maksymowych WP, Mallon C, Morrow S. et al. Development and validation of the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index. Ann Rheum Dis 2009; 68: 9489-9453
• 13 Doward LC, Spoorenberg A, Cook SA. et al. Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis 2003; 62: 20-26
• 14 Schinocca C, Rizzo C, Fasano S. et al. Role of the IL-23/IL-17 Pathway in Rheumatic Diseases: An Overview. Front Immunol 2021; 12: 637829
• 15 Taams LS, Steel KJA, Srenathan U. et al. IL-17 in the immunopathogenesis of spondyloarthritis. Nat Rev Rheumatol 2018; 14: 453-466
• 16 Lubberts E. The IL-23-IL-17 axis in inflammatory arthritis. Nat Rev Rheumatol 2015; 11: 415-429
• 17 Zhu S, Qian Y. IL-17/IL-17 receptor system in autoimmune disease: mechanisms and therapeutic potential. Clin Sci (Lond) 2012; 122: 487-511
• 18 Frleta M, Siebert S, McInnes IB. The interleukin-17 pathway in psoriasis and psoriatic arthritis: disease pathogenesis and possibilities of treatment. Curr Rheumatol 2014; 16: 414
• 19 Chen WS, Chang YS, Lin KC. et al. Association of serum interleukin-17 and interleukin-23 levels with disease activity in Chinese patients with ankylosing spondylitis. J Chin Med Assoc 2012; 75: 303-308
• 20 Wang X, Lin Z, Wei Q. et al. Expression of IL-23 and IL-17 and effect of IL-23 on IL-17 production in ankylosing spondylitis. Rheumatol Int 2009; 29: 1343-1347
• 21 Mei Y, Pan F, Gao J. et al. Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis. Clin Rheumatol 2011; 30: 269-273
• 22 Romero-Sanchez C, Jaimes DA, Londoño J. et al. Association between Th-17 cytokine profile and clinical features in patients with spondyloarthritis. Clin Exp Rheumatol 2011; 29: 828-834
• 23 Taylan A, Sari I, Kozaci DL. et al. Evaluation of the T helper 17 axis in ankylosing spondylitis. Rheumatol Int 2012; 32: 2511-2515
• 24 Milanez FM, Saad CG, Viana VT. et al. IL-23/Th17 axis is not influenced by TNF-blocking agents in ankylosing spondylitis patients. Arthritis Res Ther 2016; 24 (18) 52
• 25 Sveaas SH, Berg IJ, Provan SA. et al. Circulating levels of inflammatory cytokines and cytokine receptors in patients with ankylosing spondylitis: a cross-sectional comparative study. Scand J Rheumatol 2015; 44: 118-124
• 26 Deveci H, Caglıyan Turk A, Ozmen ZC. et al. Serum Interleukin-23/17 Levels in Ankylosing Spondylitis Patients Treated with Nonsteroidal Anti-Inflammatory Drugs: A Prospective Cohort Study. J Interferon Cytokine Res 2019; 39: 572-576
• 27 Pedersen SJ, Sørensen IJ, Garnero P. et al. ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNFα inhibitors. Ann Rheum Dis 2011; 70: 1375-1381
• 28 Melis L, Vandooren B, Kruithof E. et al. Systemic levels of IL-23 are strongly associated with disease activity in rheumatoid arthritis but not spondyloarthritis. Ann Rheum Dis 2010; 69: 618-623